Latest News & Features
Americas
The US Court of Appeals for the Federal Circuit has affirmed a district court’s decision that pharmaceutical company Tyco’s patents directed to sleep aid drug temazepam were not infringed. 7 August 2014
Americas
US District Court for the Northern District of California judge Lucy Koh has dismissed Japanese pharmaceutical company Takeda’s patent infringement case against generic maker Mylan concerning acid reflux drug Dexilant (dexlansoprazole). 6 August 2014
Biotechnology
New drugs that target ribonucleic acid (RNA) being developed by Danish biotechnology company Santaris Pharma lie behind the decision by Roche to buy Santaris that was announced yesterday, August 4. 5 August 2014
Americas
US-based injections maker Akorn has agreed to sell its rights to develop, manufacture and market generic tuberculosis injection rifampin to Watson Laboratories to settle charges by the US Federal Trade Commission (FTC) that its proposed acquisition of pharmaceutical company VersaPharm was likely to be anticompetitive. 5 August 2014
Americas
Anglo-Swedish pharmaceutical company AstraZeneca has sued India-based Zydus for infringing three patents related to its heartburn drug Nexium (esomeprazole magnesium). 4 August 2014
Americas
German pharmaceutical company Boehringer Ingelheim has sued generic drug maker Mylan for infringing a patent covering its Aggrenox drug. 31 July 2014
Americas
Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million. 31 July 2014
Americas
The expiration of US pharmaceutical company Pfizer’s patent for Viagra in many European countries was a contributing factor to the drop in revenue that it reported yesterday (July 29) when releasing its second-quarter earnings data. 30 July 2014
Big Pharma
UK-based pharmaceutical company AstraZeneca has boosted its patent portfolio with the acquisition of rights to Spanish company Almirall’s lung drugs, including Eklira (aclidinium). 30 July 2014
Americas
US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind. 29 July 2014